Drug intelligence / Profile preview

Liberdol

Development stage: Unknown
Lead developer: ViaDerma
Modality: Small Molecules
Administration: Topical

Overview

**Liberdol** is a marketed over-the-counter topical analgesic spray containing methyl salicylate, menthol, and synthetic camphor. It is applied to the affected area for temporary relief of minor muscle and joint aches and pains associated with arthritis, backache, strains, and sprains. The product is listed by DailyMed as a human OTC drug product packaged by ViaDerma Distribution. ([dailymed.nlm.nih.gov](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ab52cd0e-34fa-41c7-9ce7-1183c2aff8d8))

Brand names: Liberdol
Other names: Liberdol AnalgesicLiberdol Analgesic SprayLiberdol Topical AnalgesicLiberdol Topical Analgesic Spray

Targets

TRPM8 (Transient receptor potential cation channel subfamily M member 8)

Beyond the preview

Go deeper on Liberdol.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Liberdol.

Explore the full profile